clinical trial · NCT05764161
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
Prurigo NodularisRuxolitinib CreamVehicle Cream
brief summary
The purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
started
Jun 12, 2023
primary completion
Dec 30, 2024
completion
Nov 4, 2025
last updated
Nov 6, 2026
detailed description
The study comprises of a 12 week double-blind, vehicle-controlled (DBVC) treatment period, followed by a 40 week open label extension period, and 30 day safety follow-up period During the double blind period, all PN-affected areas identified at baseline will be treated, and during the open label period, only active PN-affected areas will be treated.
official title
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol